N-BOC-2-氨基-5-溴噻唑 | 405939-39-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: N-BOC-2-氨基-5-溴噻唑
• 中文别名: N-叔丁氧羰基-2-氨基-5-溴噻唑；5-溴-2-(N-甲酸叔丁酯)氨基噻唑
• 英文名称: tert-butyl 5-bromothiazol-2-ylcarbamate
• 英文别名: tert-butyl N-(5-bromo-1,3-thiazol-2-yl)carbamate；(5-bromo-thiazol-2-yl)-carbamic acid tert-butyl ester；tert-butyl N-(5-bromothiazol-2-yl)carbamate；N-Boc-2-Amino-5-bromothiazole
• CAS: 405939-39-1
• 化学式: C₈H₁₁BrN₂O₂S
• mdl: MFCD07368614
• 分子量: 279.158
• InChiKey: OIBKBVFFZYCBAQ-UHFFFAOYSA-N

物化性质

• 熔点：
  149 °C
• 密度：
  1.574±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Boc-2-amino-5-bromothiazole
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Boc-2-amino-5-bromothiazole
Ingredient name:
CAS number: 405939-39-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H11BrN2O2S
Molecular weight: 279.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-BOC-2-氨基-5-溴噻唑 在 bis-triphenylphosphine-palladium(II) chloride 氢氧化钾 、 copper(l) iodide 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 tert-butyl 5-ethynylthiazol-2-ylcarbamate
  参考文献：
  名称：

  WO2008/154642

  摘要：

  公开号：
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 4-二甲氨基吡啶 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成 N-BOC-2-氨基-5-溴噻唑
  参考文献：
  名称：

  [EN] TRICYCLIC PYRAZOL AMINE DERIVATIVES
  [FR] DÉRIVÉS TRICYCLIQUES DE PYRAZOLAMINE

  摘要：

  这项发明涉及到 Formula (I*) 的化合物作为 Pi3k 抑制剂，用于治疗自身免疫疾病、炎症性疾病、多发性硬化等疾病，以及癌症等其他疾病。

  公开号：

  WO2011058149A1

文献信息

• [EN] TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPES AU GLUTAMATE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012006760A1

  公开（公告）日：2012-01-19

  The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -Cl or -Br. In Formula (II), R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-O-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently -H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (O=), which together with the carbon to which they are attached forms a carbonyl group.

  本发明描述和声明了结构式（I）、结构式（II）或结构式（III）的化合物。在结构式（I）中，R1、R2、R3和R3'为-H或甲基，或R3和R3'一起形成双键，或R3'为-H且R2和R3一起形成螺环丙基取代基，R4为-H或-F，R5为-H、甲基、-Cl或-Br。在结构式（II）中，R1为-H、乙基、异丙基、环丙基、甲基或甲氧基，R4为-H或-F，“Y”为：（a）-CH2-；（b）-CR6H-O-CR7R8-，其中R6、R7和R8独立地为-H或甲基；（c）-CR6H-N（R9）-CR7R8-，其中R6、R7和R8独立地为-H或甲基；（d）-CH2-C（R9）（R10）-C（R7）（R8）-，其中R7、R8、R9和R10独立地为-H或-甲基，或R7和R8都为-F，R9和R10独立地为-H或-甲基，或R9和R10都为-F，或R9和R10一起为（O=），与它们连接的碳一起形成羰基。
• Preparation of 3,4-Substituted-5-Aminopyrazoles and 4-Substituted-2-Aminothiazoles
  作者：Stepan Havel、Prashant Khirsariya、Naresh Akavaram、Kamil Paruch、Benoit Carbain

  DOI：10.1021/acs.joc.8b02655

  日期：2018.12.21

  3,4-Substituted-5-aminopyrazoles and 4-substituted-2-aminothiazoles are frequently used intermediates in medicinal chemistry and drug discovery projects. We report an expedient flexible synthesis of 3,4-substituted-5-aminopyrazoles (35 examples), based on palladium-mediated α-arylation of β-ketonitriles with aryl bromides. A library of 4-substituted-2-aminothiazoles (21 examples) was assembled by a

  3,4-取代的5-氨基吡唑和4-取代的2-氨基噻唑是药物化学和药物开发项目中经常使用的中间体。我们报道了基于钯介导的β-酮腈与芳基溴化物的α-芳基化反应的3,4-取代的5-氨基吡唑类化合物的便捷合成（35个例子）。通过使用新制备的，适当保护的4-硼酸-2-氨基噻唑的频哪醇酯和MIDA酯与（杂）芳基卤化物的Suzuki偶联的序列，组装4-取代的2-氨基噻唑的文库（21个实例）。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2016046530A1

  公开（公告）日：2016-03-31

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

  本发明涉及新型化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C端水解酶L1（UCHL1）。本发明进一步涉及在癌症和其他适应症治疗中使用DUB抑制剂。本发明的化合物包括具有式（I）或其药用可接受盐的化合物，其中R1至R8如本文所定义。
• [EN] N1 -(4-(5-(CYCLOPROPYLMETHYL)-1 -METHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAKI INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE N1 -(4-(5-(CYCLOPROPYLMÉTHYL)-1 -MÉTHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS DE CK1 ET/OU D'IRAKI POUR LE TRAITEMENT DU CANCER
  申请人：YISSUM RES DEVELOPMENT COMPANY OF THE HEBREW

  公开号：WO2018142393A1

  公开（公告）日：2018-08-09

  The present invention provides pyrazole derivatives of Formula (I), and in particular N1-(4-(5-(cyclopropylmethyl)-1-methyl-lH-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as casein kinase 1 (CK1) and/or interleukin 1 receptor associated kinase 1 (IRAKI) inhibitors for treating cancer, inflammatory and immune related disorders.

  本发明提供了式(I)的吡唑衍生物，特别是N1-(4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)吡啶-2-基)环己烷-1,4-二胺衍生物及相关化合物，作为治疗癌症、炎症和免疫相关疾病的酪蛋白激酶1（CK1）和/或白细胞介素1受体相关激酶1（IRAK1）抑制剂。
• Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs
  作者：Andrew J. Harvey、Thomas D. Avery、Laurent Schaeffer、Christophe Joseph、Belinda C. Huff、Rajinder Singh、Christophe Morice、Bruno Giethlen、Anton A. Grishin、Carolyn J. Coles、Peter Kolesik、Stéphanie Wagner、Emile Andriambeloson、Bertrand Huyard、Etienne Poiraud、Dharam Paul、Susan M. O’Connor

  DOI：10.1021/acsmedchemlett.9b00001

  日期：2019.5.9

  whereas Type II PAMs both increase channel response and delay receptor desensitization. Both Type I and Type II PAMs are reported in literature, but there are limited reports describing their structure-kinetic profile relationships. Here, we report a novel class of compounds with either Type I or Type II behavior that can be tuned by the relative stereochemistry around the central cyclopropyl ring: for example

  就其对通道动力学的影响而言，α7nAChRs的正变构调节剂（PAM）可能具有不同的特性。I型PAM会放大对乙酰胆碱的峰通道响应，但似乎不会影响通道脱敏动力学，而II型PAM会增加通道响应并延迟受体脱敏。I型和II型PAM均在文献中进行了报道，但很少有报道描述它们的结构动力学轮廓关系。在这里，我们报告了一类具有I型或II型行为的新型化合物，可以通过围绕中央环丙基环的相对立体化学进行调节：例如（R，R）-13（BNC375）及其具有RR立体化学的类似物I型PAM位于中央环丙基环周围，而具有SS立体化学的同一系列化合物（例如，（S，S）-13）是使用膜片钳电生理学测量的II型PAM。通过改变苯胺环上的取代基可实现对动力学的进一步精细控制：通常，苯胺被强吸电子基团取代会降低这些化合物的II型特性。我们通过结构活性优化工作发现了BNC375，这是一种具有良好CNS-药物样性质和临床候选潜力的小分子。